Arena Pharmaceuticals to Announce Second Quarter 2004 Financial Results and to Host Conference Call and Webcast on Tuesday, July 20, 2004
SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the company will release second quarter
2004 financial results after the NASDAQ National Market closes on Tuesday,
July 20, 2004. Arena also announced today that Jack Lief, President and Chief
Executive Officer of Arena, will host a conference call to discuss the
financial results and corporate highlights from the second quarter. The call
will take place on Tuesday, July 20, 2004, at 5:00 PM Eastern Time (2:00 PM
The conference call may be accessed by dialing (888) 273-9887 for domestic
callers and (612) 332-0820 for international callers. Please specify to the
operator that you would like to join the "Arena Pharmaceuticals Second Quarter
Earnings Conference Call." The conference call will be webcast live on
Arena's website at http://www.arenapharm.com, under the investor relations
section, and will be archived there for 30 days following the call. Please
connect to Arena's website several minutes prior to the start of the
conference call to ensure adequate time for any software download that may be
Arena is a biopharmaceutical company focusing on the discovery,
development and commercialization of drugs in four major therapeutic areas:
metabolic, cardiovascular, central nervous system and inflammatory diseases.
Arena is developing a broad pipeline of compounds including one in Phase 1
clinical trials for obesity and another in preclinical development for
insomnia. The company's compounds act on an important class of drug targets
called G protein-coupled receptors, or GPCRs, and were developed using Arena's
proprietary technologies, including CART (Constitutively Activated
Receptor Technology) and Melanophore. Arena also has research collaborations
with Merck, Fujisawa, Taisho and TaiGen for products in a number of different
indications. For additional information about Arena, please visit their
website at http://www.arenapharm.com.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, technologies,
preclinical and clinical programs, future achievements, and statements that
are not historical facts, including statements about Arena's ability to
identify and develop drugs or which are preceded by the word "will" or similar
words. For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Important factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's SEC reports, including
Arena's most recent quarterly report on Form 10-Q. These forward-looking
statements represent Arena's judgment as of the date of this release. Arena
disclaims any intent or obligation to update these forward-looking statements.
For further information please contact Jack Lief of Arena Pharmaceuticals,
+1-858-453-7200, ext. 223; or Susan Neath of Atkins + Associates,
+1-858-527-3486, for Arena Pharmaceuticals.
SOURCE Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com
You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.